Zhu Shigui

发表

Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.

A. Liang, Jiaqi Huang, Yihong Yao, 2021 .

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

M. Humphries, Jiaqi Huang, Yihong Yao, 2020 .